Upstream Bio, Inc. (UPB) - Total Assets
Based on the latest financial reports, Upstream Bio, Inc. (UPB) holds total assets worth $281.17 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Upstream Bio, Inc. - Total Assets Trend (2022–2025)
This chart illustrates how Upstream Bio, Inc.'s total assets have evolved over time, based on quarterly financial data. Also see market cap of Upstream Bio, Inc. for the company's overall valuation and market capitalisation.
Upstream Bio, Inc. - Asset Composition Analysis
Current Asset Composition (December 2025)
Upstream Bio, Inc.'s total assets of $281.17 Million consist of 99.4% current assets and 0.6% non-current assets. Review UPB liabilities breakdown to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 28.7% |
| Accounts Receivable | $668.00K | 0.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how Upstream Bio, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Upstream Bio, Inc. (UPB) stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Upstream Bio, Inc.'s current assets represent 99.4% of total assets in 2025, an increase from 99.1% in 2022.
- Cash Position: Cash and equivalents constituted 28.7% of total assets in 2025, down from 92.3% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is accounts receivable at 0.2% of total assets.
Upstream Bio, Inc. Competitors by Total Assets
Key competitors of Upstream Bio, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $752.18 Million |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Biohaven Ltd.
NYSE:BHVN
|
USA | $466.41 Million |
|
Galapagos NV
F:GXEA
|
Germany | €3.37 Billion |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068
|
China | CN¥3.21 Billion |
Upstream Bio, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 27.99 | 38.27 | 17.96 |
| Quick Ratio | 27.99 | 38.27 | 17.96 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $269.61 Million | $407.34 Million | $110.48 Million |
Upstream Bio, Inc. - Advanced Valuation Insights
This section examines the relationship between Upstream Bio, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.25 |
| Latest Market Cap to Assets Ratio | 0.80 |
| Asset Growth Rate (YoY) | -26.6% |
| Total Assets | $353.77 Million |
| Market Capitalization | $284.26 Million USD |
Valuation Analysis
Below Book Valuation: The market values Upstream Bio, Inc.'s assets below their book value (0.80x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Upstream Bio, Inc.'s assets decreased by 26.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Upstream Bio, Inc. (2022–2025)
The table below shows the annual total assets of Upstream Bio, Inc. from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $353.77 Million | -26.56% |
| 2024-12-31 | $481.72 Million | +311.03% |
| 2023-12-31 | $117.20 Million | +534.26% |
| 2022-12-31 | $18.48 Million | -- |
About Upstream Bio, Inc.
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.… Read more